An interventional study of Standard Hypertension Education and Generative AI-Supported Personalized Hypertension Education in Hypertansion, sponsored by Akdeniz University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Akdeniz University · Not applicable, Interventional, and Health services research
This study evaluates whether generative artificial intelligence-supported personalized education can improve hypertension knowledge and medication adherence in adults with hypertension compared with standard printed educational material. A total of 88 adults with hypertension are included in the study. Participants are assigned to either an intervention group or a control group. The control group receives a printed hypertension education booklet. The intervention group receives personalized educational content prepared using generative artificial intelligence based on individual characteristics and needs, together with weekly WhatsApp or SMS messages, voice messages, and brief telephone follow-up. The intervention lasts four weeks, and final assessments are performed in the fifth week. Hypertension knowledge, medication adherence self-efficacy, and blood pressure are assessed before and after the intervention. It is expected that personalized education will improve hypertension knowledge and medication adherence compared with printed education.
937 studies on the registry are indexed under Medication Adherence; 159 are open to participants now.
This study's enrollment of 88 is below the median of 120 across 768 interventional studies indexed under Medication Adherence.
Browse Medication Adherence studies →Akdeniz University is the lead sponsor of 297 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm receive standard hypertension education and a printed hypertension education booklet. Baseline assessments and blood pressure measurements are performed in the first week. In the fifth week, post-intervention assessments and blood pressure measurements are repeated.
Behavioral: Standard Hypertension Education
Participants in this arm receive generative artificial intelligence-supported personalized hypertension education based on their individual characteristics, needs, baseline information, and the standardized hypertension education content. The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages. Brief structured telephone follow-up is conducted during the first and fourth weeks. In the fifth week, post-intervention assessments and blood pressure measurements are performed.
Behavioral: Generative AI-Supported Personalized Hypertension Education
Participants receive standard hypertension education including medication-related information and a printed hypertension education booklet developed based on expert recommendations.
Participants receive personalized hypertension education generated using generative artificial intelligence based on individual characteristics, needs, baseline information, and standardized hypertension education content. The intervention is delivered over four weeks through weekly WhatsApp or SMS messages and voice messages. Brief structured telephone follow-up is provided in the first and fourth weeks.
Mean Change From Baseline in Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF) Total Score at Week 5
Medication adherence self-efficacy will be assessed using the 13-item Medication Adherence Self-Efficacy Scale-Short Form (MASES-SF). Each item is scored from 1 (not at all sure) to 4 (very sure), resulting in a total score ranging from 13 to 52. Higher scores indicate greater self-efficacy for adhering to antihypertensive medication. The change in total score from baseline to Week 5 will be evaluated.
Time frame: Baseline and Week 5
Mean Change From Baseline in Hypertension Knowledge-Level Scale (HK-LS) Total Score at Week 5
Hypertension knowledge will be assessed using the 22-item Hypertension Knowledge-Level Scale (HK-LS). The scale includes six domains: definition, medical treatment, medication adherence, lifestyle, diet, and complications. Responses are recorded as true, false, or do not know, and each correct response receives 1 point. Higher scores indicate greater hypertension knowledge, and a score of 16 or above indicates a high level of hypertension knowledge. The change in total score from baseline to Week 5 will be evaluated.
Time frame: Baseline and Week 5
Mean Change From Baseline in Systolic Blood Pressure at Week 5
Systolic blood pressure will be measured in mmHg at baseline and Week 5. The change in systolic blood pressure from baseline to Week 5 will be evaluated.
Time frame: Baseline and Week 5
Mean Change From Baseline in Diastolic Blood Pressure at Week 5
Diastolic blood pressure will be measured in mmHg at baseline and Week 5. The change in diastolic blood pressure from baseline to Week 5 will be evaluated.
Time frame: Baseline and Week 5
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 425 non-industry interventional studies with no phase under Medication Adherence, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 6 months is below that.
Counting every sponsor, half of 442 studies reached it within 21 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.